Detalhe da pesquisa
1.
Comparative Treatment of Mucocutaneous Lesions in Hereditary Haemorrhagic Telangiectasia Patients With Dual Sequential Pulsed Dye Laser and Neodymium: Yttrium-Aluminium-Garnet Versus Neodymium: Yttrium-Aluminium-Garnet Laser Alone: A Double-Blind Randomized Controlled Study With Quality-of-Life Evaluation.
Actas Dermosifiliogr
; 115(3): 246-257, 2024 Mar.
Artigo
em Inglês, Espanhol
| MEDLINE | ID: mdl-37913989
2.
Comparative Treatment of Mucocutaneous Lesions in Hereditary Haemorrhagic Telangiectasia Patients With Dual Sequential Pulsed Dye Laser and Neodymium: Yttrium-Aluminium-Garnet Versus Neodymium: Yttrium-Aluminium-Garnet Laser Alone: A Double-Blind Randomized Controlled Study With Quality-of-Life Evaluation. / [Artículo traducido] Tratamiento comparativo de lesiones mucocutáneas en pacientes con telangiectasia hemorrágica hereditaria con láser dual secuencial de colorante pulsado y neodimio: itrio-aluminio-granate versus neodimio: itrio-aluminio-granate solo: un estudio controlado aleatorizado doble ciego con evaluación de la calidad de vida.
Actas Dermosifiliogr
; 115(3): T246-T257, 2024 Mar.
Artigo
em Inglês, Espanhol
| MEDLINE | ID: mdl-38185205
3.
[[Translated article]]Recommendations from the Spanish Academy of Dermatology and Venereology Psoriasis Working Group on the Management of Patients with Cancer and Psoriasis. / Recomendaciones del Grupo de Psoriasis de la Academia Española de Dermatología y Venereología sobre el manejo de la psoriasis en pacientes oncológicos.
Actas Dermosifiliogr
; 2024 May 29.
Artigo
em Inglês, Espanhol
| MEDLINE | ID: mdl-38821353
4.
Recommendations from the Spanish Academy of Dermatology and Venereology Psoriasis Working Group on the Management of Patients with Cancer and Psoriasis. / Recomendaciones del Grupo de Psoriasis de la Academia Española de Dermatología y Venereología sobre el manejo de la psoriasis en pacientes oncológicos.
Actas Dermosifiliogr
; 2024 Feb 19.
Artigo
em Inglês, Espanhol
| MEDLINE | ID: mdl-38382743
5.
Persistence and effectiveness of guselkumab treatment in patients with moderate-to-severe plaque psoriasis in a non-interventional real-world setting: The SPRING study.
J Eur Acad Dermatol Venereol
; 2023 Aug 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37567861
6.
Statins and psoriasis: Position statement by the Psoriasis Task Force of the European Academy of Dermatology and Venerology.
J Eur Acad Dermatol Venereol
; 37(9): 1697-1705, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37259959
7.
Updated Position of the Spanish Psoriasis Group (GPs) on the Use of Biosimilar Drugs in Moderate to Severe Psoriasis. / Actualización en el posicionamiento del Grupo Español de Psoriasis (GPS) en la utilización de medicamentos biosimilares en psoriasis moderada-grave.
Actas Dermosifiliogr
; 114(6): 494-501, 2023 Jun.
Artigo
em Inglês, Espanhol
| MEDLINE | ID: mdl-36906260
8.
Long-term efficacy and safety of brodalumab in moderate-to-severe plaque psoriasis: a post hoc pooled analysis of AMAGINE-2 and -3.
J Eur Acad Dermatol Venereol
; 36(8): 1275-1283, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-35279890
9.
Prevalence of most common skin diseases in Europe: a population-based study.
J Eur Acad Dermatol Venereol
; 36(7): 1088-1096, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35274366
10.
Nail Psoriasis. / Psoriasis ungueal.
Actas Dermosifiliogr
; 113(5): 481-490, 2022 May.
Artigo
em Inglês, Espanhol
| MEDLINE | ID: mdl-35697407
11.
Practical update of the Recommendations Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (GPS) on the Treatment of Psoriasis with Biologic Therapy. Part 1. Concepts and General Management of Psoriasis with Biologic Therapy. / Actualización práctica de las recomendaciones del Grupo de Psoriasis de la Academia Española de Dermatología y Venereología (GPS) para el tratamiento de la psoriasis con terapia biológica. Parte 1. «Conceptos y manejo general de la psoriasis con terapia biológica¼.
Actas Dermosifiliogr
; 113(3): 261-277, 2022 Mar.
Artigo
em Inglês, Espanhol
| MEDLINE | ID: mdl-35526919
12.
Practical Update of the Guidelines Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (GPs) on the Treatment of Psoriasis With Biologic Agents: Part 2 - Management of Special Populations, Patients With Comorbid Conditions, and Risk. / Actualización práctica de las recomendaciones del Grupo de Psoriasis de la Academia Española de Dermatología y Venereología (GPS) para el tratamiento de la psoriasis con terapia biológica. Parte 2 «Manejo de poblaciones especiales, pacientes con comorbilidad y gestión del riesgo¼.
Actas Dermosifiliogr
; 113(6): 583-609, 2022 Jun.
Artigo
em Inglês, Espanhol
| MEDLINE | ID: mdl-35570005
13.
Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up.
Br J Dermatol
; 185(6): 1135-1145, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34157132
14.
Risk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey.
Br J Dermatol
; 185(1): 80-90, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33368145
15.
Complete clearance and psoriasis area and severity index response for brodalumab and ustekinumab in AMAGINE-2 and -3.
J Eur Acad Dermatol Venereol
; 35(2): 450-457, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-32662540
16.
Complete clearance and Psoriasis Area and Severity Index response for brodalumab and ustekinumab by previous treatment history in AMAGINE-2 and AMAGINE-3.
J Eur Acad Dermatol Venereol
; 35(10): 2034-2044, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34076919
17.
Definition of minimal disease activity in psoriasis.
J Eur Acad Dermatol Venereol
; 35(2): 422-430, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-32367536
18.
Position statement for a pragmatic approach to immunotherapeutics in patients with inflammatory skin diseases during the coronavirus disease 2019 pandemic and beyond.
J Eur Acad Dermatol Venereol
; 35(4): 797-806, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33533553
19.
Adjusted treatment COMPArisons between guSelkumab and uStekinumab for treatment of moderate-to-severe plaque psoriasis: the COMPASS analysis.
Br J Dermatol
; 183(2): 276-284, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31652347
20.
Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study.
Br J Dermatol
; 182(2): 304-315, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31102257